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Abstract: Obstructive sleep apnea (OSA) is a form of sleep disordered breathing char-
acterized by episodes of apnea (during sleep) lasting at least 10 seconds per episode. The 
apneic periods are associated with arterial hypoxemia and disruption of normal sleep as a 
result of awakenings. It is increasingly being recognized that OSA is a public health hazard 
and there is increasing evidence that it is associated with an increase in morbidity (and pos-
sibly mortality). Patients with OSA also utilize the healthcare resources at higher rates than 
control patients long before their diagnosis is conﬁ  rmed. Early recognition of this condition 
may lead to earlier treatments (eg, nasal CPAP) with reduction of the risk of cardiovascular 
diseases such as hypertension, ischemic heart disease, arrhythmias, platelet activation and 
pulmonary hypertension.
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Epidemiology of OSA
Early observational studies linked snoring to increased cardiac events. However, sub-
sequent studies demonstrated a clear relationship between the presence and severity of 
obstructive sleep apnea (OSA) with systemic hypertension and increased cardiovascular 
disease. The initial descriptions of OSA were that of severe apnea in obese, middle-
aged male subjects (Block et al 1979). OSA syndrome is a common breathing disorder 
that affects 2%–4% of the adult population with men being affected almost twice as 
much compared to women (Young et al 1993). In a later study, women accounted for 
one third of OSA patients (Edwards et al 1998).
Pathophysiologic mechanisms of cardiovascular 
disease in OSA
Pathophysiology of OSA
Obstructive sleep apnea is the most common form of sleep disordered breathing (SDB) 
and characterized by repetitive partial or complete closure of the upper airway during 
sleep. Acute physiologic stresses occur during these episodes of asphyxia, including 
arterial oxygen desaturation, surges in sympathetic activity, and acute hypertension.
Obstructive sleep apnea results in hypoxemia and hypercapnea and contributes to 
arousals which are frequently associated with it and leads to an increase in myocardial 
oxygen demand. The hypoxemia and hypercapnea as well as the associated arousals, 
activate the sympathetic nervous system and increases catecholamine release which 
further aggravates the myocardial oxygen demand. The ensuing hypertension and 
associated cardiac ischemia and hypertrophy, lead to a propensity for arrhythmias and 
an increase in LV wall tension and consequently, congestive heart failure. In a study 
by Dursunoglu et al (2005) of 67 patients without previous cardiac and pulmonary 
disease who were diagnosed as having mild, moderate or severe OSA, LV hypertrophy 
and LV mass index, on echocardiographic criteria, was higher in those with moderate Therapeutics and Clinical Risk Management 2007:3(6) 1106
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to severe OSA compared with those with mild sleep apnea. 
However, in this study hypertension was also more prevalent 
in those with moderate and severe OSA.
Patients also develop a hypercoagulable state as a result of 
platelet activation which further aggravates the heart failure 
(Bradley and Floras 2003).
OSA, COPD 
and pulmonary hypertension
The prevalence of OSA in predominantly mild COPD patients 
is not greater than in the general population, but the two condi-
tions frequently coexist. This association is thought to occur 
by chance and is not pathophysiologically linked (Sanders 
et al 2003). The association of OSA with COPD (‘overlap 
syndrome’) is also signiﬁ  cant in that a large epidemiologic 
study by Sanders et al have demonstrated greater reductions 
in nocturnal oxygen saturations than either alone. Conven-
tional domiciliary oxygen therapy (daytime and nocturnal) is 
indicated in COPD patients with marked daytime hypoxemia 
(PaO2   55–60 mmHg) and there is insufﬁ  cient data on the 
use of nocturnal O2 therapy in COPD patients with nocturnal 
desaturation without daytime hypoxemia (PaO2   60 mmHg) 
(Weitzenblum and Chaouat 2004).
Alveolar hypoxemia is also the most important mecha-
nism leading to pulmonary vasoconstriction, pulmonary 
vascular remodeling and pulmonary hypertension. Some 
evidence suggests that patients with OSA and COPD are at 
greater risk of pulmonary hypertension than patients with 
sleep apnea alone (Chaouat et al 1995; Hawrylkiewicz et 
al 2004).
In patients with severe COPD a reduction in oxygen 
saturation during sleep was twice as much as that during 
maximal exercise (Mulloy and McNicholas 1996). Patients 
with obstructive sleep apnea as well as COPD (‘overlap 
syndrome’) are associated with a greater risk of pulmonary 
hypertension. It has been observed that patients with COPD 
who are hypoxemic during wakefulness are at greater risk of 
hypoxemia during sleep and usually more profound during 
REM sleep (Wynne et al 1979). These desaturations are not 
only present during REM sleep, but also during the earlier 
stages of non-REM sleep (Stages 1 and 2), and are not as 
severe (Kurtz et al 1987; Mulloy and McNicholas 1996). In 
a small study of 40 patients by Vos et al (1995) to determine 
predictors of nocturnal desaturations in COPD, only a small 
number of patients with mild to moderate daytime hypoxemia 
(PaO2 60–80 mmHg) had nocturnal desaturations with mean 
arterial O2 saturations below 90%. These patients also had 
a lower hypercapneic ventilatory response, and no patients 
with daytime PaO2   80 mmHg had nocturnal desaturations 
(Vos et al 1995).
Earlier reports have hypothesized that COPD patients with 
moderate hypoxia (PaO2 56–69) were at risk of nocturnal oxy-
gen desaturations and subsequent pulmonary hypertension. 
In a study published by Chaouat et al (1997) of 94 patients 
with COPD randomized to saturators (group 1) and desatura-
tors (group 2 : O2 saturation  30% of time less than 90%,) it 
has been concluded that there are no individual variables or 
combination of variables (except PaCO2 which was higher 
in the desaturators) that predicted the presence of pulmonary 
hypertension, and that the mean pulmonary artery pressure 
did not correlate with the degree and duration of nocturnal 
hypoxemia (Bradley et al 1990; Chaouat et al 1997).
The two mechanisms responsible for the worsening of 
hypoxemia during sleep are alveolar hypoventilation and 
ventilation-perfusion (V/Q) mismatching. Apneas generally 
do not occur in COPD patients unless they are associated with 
OSA. Transient hypoxemia which may occur during sleep in 
patients with COPD has been stated not to be a sleep apnea 
syndrome (Chatterhall et al 1983).
Pulmonary hypertension in patients with COPD has tra-
ditionally been explained on the basis of hypoxic pulmonary 
vasoconstriction. Christensen et al (2004) studied 17 patients 
with COPD of varying severity with no or mild hypoxemia at 
rest and during their exercise equivalent of their activities of 
daily living (ADLs). In their study, they have demonstrated 
that exercise-induced pulmonary hypertension occurred in 
65% of patients, and that the increase in pulmonary artery 
pressure was negatively correlated with arterial oxygen ten-
sions. In addition, patients with exercise-induced pulmonary 
hypertension were not invariably accompanied by hypoxemia 
and not all patients with exercise-induced hypoxemia had 
pulmonary hypertension. Their study also demonstrated a 
negative correlation between pulmonary vascular resistance 
index (PVRI) and arterial oxygen tension during exercise, but 
also an elevated PVRI occurred in 35% of patients without 
exercise-induced hypoxemia. The authors concluded that 
mechanisms other than hypoxemia, such as arterial remod-
eling due to inﬂ  ammation may contribute to pulmonary 
hypertension in these patients (Christensen et al 2004).
With reference to the association of OSA and pulmonary 
arterial hypertension (PAH), the American College of Chest 
Physicians has provided clinical practice guidelines in an 
evidence-based approach. Based on the available evidence 
the following recommendations have been made:
1.  In the evaluation of patients with PAH, an assessment 
of sleep disordered breathing (SDB) is recommended Therapeutics and Clinical Risk Management 2007:3(6) 1107
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using polysomnography if OSA is suspected either by 
high clinical suspicion or if a screening test result is 
positive.
2.  In the management of patients with OSA, the routine eval-
uation for the presence of PAH is not recommended.
3.  In patients with both OSA and PAH, treatment of OSA 
with positive pressure ventilation should be provided 
with the expectation that the pulmonary pressures may 
be reduced but not normalized, especially in patients with 
more severe PAH (Atwood et al 2004).
OSA and sytemic hypertension
There is increasing evidence that hypertension is associated 
with sleep apnea syndromes. Both case control and cross-
sectional studies have demonstrated a higher prevalence of 
hypertension in patients with OSA (50%–90%). Dhillon 
et al (2005) in an observational review of 180 consecutive 
charts from 1995 to 2002, studied patients with OSA from 
an urban and a rural sample, who were either hypertensive or 
normotensive. Their study demonstrated that 28% (50/180) 
of patients were hypertensive and that treatment with CPAP 
for an average of 12 months was associated with signiﬁ  cant 
reduction in systolic and diastolic blood pressures (11 mmHg 
vs 6 mmHg respectively) and consequently a reduction in 
cardiovascular risk. This study conﬁ  rms the relationship of 
sleep apnea and hypertension and the beneﬁ  t of CPAP as 
reported in other studies (Dhillon et al 2005). Other studies 
have also demonstrated that CPAP treatment of OSA patients 
with hypertension, have led to a lowering of blood pressures 
resulting in a reduced cardiovascular risk (Tilkian et al 1976; 
Millman 1991).
Subjects with an apnea-hypopnea index (AHI)   5 have 
a higher incidence of systolic and diastolic hypertension. 
Sleep apnea has been shown to occur frequently in patients 
with essential hypertension (22%–62%) (Lavie et al 1984). 
In a study of 23 patients treated for essential hypertension, 
using a questionnaire for symptoms of sleep apnea, and a 
sleep study, the prevalence of sleep apnea was 48% (11/23). 
Of these patients, one third (7/11) were found to have severe 
oxygen desaturations deﬁ  ned as at least a 4% reduction or 
saturations   90% (average 87%) during sleep as a result of 
apnea (Williams et al 1985).
In some of the earlier studies or surveys, there had been 
no objective data on breathing during sleep and it is not 
clear if the association was due to the inclusion of apneic 
individuals among snorers. Inconsistencies in the association 
of sleep apnea and hypertension have been demonstrated, 
with some studies showing a strong association and others 
not. These inconsistencies were probably related to differ-
ences in deﬁ  nitions of hypertension and apnea, as well as the 
inability to control for factors associated with hypertension 
such as obesity and diabetes. In one of the largest cohort of 
6,132 subjects (Sleep Heart Health Study), it has been clearly 
demonstrated that sleep disordered breathing is associated 
with systemic hypertension in middle-aged and older-aged 
individuals of different sexes and ethnic backgrounds even 
after adjusting for variables such as body mass index (BMI), 
neck circumference, waist-to-hip ratio, alcohol intake and 
smoking. In the unadjusted arm of the study, the prevalence 
rates of hypertension increased according to the severity of 
the apnea (43% (AHI   1.5), 53% (AHI 1.5–4.9), 59% (AHI 
5–14.9), 62% (AHI 15–29.9) and 67% with an AHI   30. 
When adjusted for other demographics, the odds of hyperten-
sion increased in a graded response according to the severity 
of the AHI (Nieto et al 2000). In another large cohort of 709 
patients (Wisconsin Sleep Study) it has been demonstrated 
that there was a dose-response association with hypertension 
and the severity of sleep apnea according to their AHI, even 
after adjusting for other factors such as BMI, alcohol and 
tobacco use (Peppard et al 2000).
A cross-sectional community based study of 147 male 
and female patients (30–60 years) selected from the Wiscon-
sin Sleep Cohort Study looked at the association of blood 
pressure during sleep and wakefulness in patients with and 
without sleep apnea. In this study, the mean blood pressures 
were signiﬁ  cantly elevated in patients with sleep apnea during 
wakefulness (131/80 ± 1.7/1.1 mmHg) compared to 122/75 
± 1.9/1.2 mmHg in those without sleep apnea. In addition the 
mean blood pressures in sleep apnea patients during sleep 
were also signiﬁ  cantly elevated (113/66 ± 1.8/1.1 mmHg, 
compared to 104/62 ± 2/1.3 mmHg, P   0.05). The study also 
demonstrated the variability of the blood pressure during sleep 
was signiﬁ  cantly greater in participants with sleep apnea or a 
history of snoring compared with those without. The variability 
in mean arterial blood pressure in non-snorers with an AHI   5 
was 7.5 mmHg compared to 8.5 mmHg in snorers with an AHI 
  5 and 8.9 in apneic patients with AHI   5 (P   0.05). Even 
after controlling for obesity, gender and age, the prevalence 
of hypertension was signiﬁ  cantly associated with sleep apnea 
(OR 2.0 to 5.0 for AHI 5–25) (Hla et al 1994).
Studies have also shown higher sympathetic activity 
in sleep apnea patients when awake, with further increases 
during sleep. The greatest increase in sympathetic activity is 
at the end of the apnea period, after arousal. With resump-
tion of normal breathing, there is a decrease in sympathetic 
activity and blood pressure. The mechanism(s) of increased Therapeutics and Clinical Risk Management 2007:3(6) 1108
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sympathetic nervous activity is unclear but may be deter-
mined by factors such as age, sex, obesity, oxygen desatura-
tion and hypercapnea. Continuous positive airway pressure 
(CPAP) has been shown to attenuate the apneic episodes as 
well as the increased sympathetic activity and hypertensive 
responses during sleep. However, this attenuated response is 
not complete to the levels seen during normal sleep in normal 
subjects (Somers 1993, 1995).
The arousal mechanism has been considered a stimulant 
of sympathetic activity and catecholamine levels have been 
shown to be increased after arousal. Carotid body stimulation 
appears to be pivotal to this sympathetic nervous activity 
and the development of increases in blood pressure. Oxygen 
attenuates the sympathetic nervous system responses to 
apnea, but does not completely inhibit it. In a more recent 
study in hypertensive patients with OSA who are hypersom-
nolent compared with those that are non-hypersomnolent, 
there has been no signiﬁ  cant difference in the mean 24-hour 
BP when CPAP treatment was compared to sham treatment 
(suboptimal CPAP) (Robinson et al 2006).
Sleep disordered breathing (SDB) has also been linked 
to the development of stroke. Until recently there have been 
no prospective studies that have conﬁ  rmed the association of 
SDB with stroke. In a cross-sectional and longitudinal study 
published by Arzt et al (2005), subjects with SDB were com-
pared with those without SDB in the general population and 
followed for 4 years for the development of stroke. Of 1475 
subjects studied in the cross-sectional analysis, 22 suffered 
a ﬁ  rst-ever stroke over the next 4 years and none of these 
had atrial ﬁ  brillation. The percent prevalence rates for stroke 
according to AHI’s of  5, 5 to  20 and  20 were 1.2%, 0.8% 
and 6.1% respectively. After adjustment for age, sex, body 
mass index, smoking and alcohol consumption, the odds ratio 
for developing a stroke in the SDB group was still elevated 
(O.R. 4.3 for AHI   20, 95% C.I 1.32–14.24 ). When hyper-
tension was added as a confounding variable, the odds ratio 
was 3.87 (95% C.I. 1.19–12.63) and remained signiﬁ  cant. In 
the group with mild to moderate SDB (AHI 5.0 –  20.0) the 
odds ratio for the prevalence of stroke was not signiﬁ  cantly 
different from the reference group (AHI   5.0). This study 
however, does demonstrate an association with SDB and the 
development of stroke even after adjusting for confounding 
factors (Artz et al 2005).
OSA and ischemic heart disease
Increasing evidence is emerging that indicate that OSA is a 
risk factor for cardiovascular disease, independent of other 
commonly associated conditions such as age, sex, obesity, 
diabetes and hypertension. Earlier epidemiologic studies, 
using snoring as a surrogate for OSA, suggested a higher 
prevalence of hypertension and ischemic heart disease in 
snorers (Yates 1987; Markku et al 1985; Norton and Dunn 
1985).
Hung et al studied 101 unselected male survivors 
( 65yrs) of acute myocardial infarction (MI) and another 
53 male subjects of similar age without evidence of ischemic 
heart disease. The apnea index was 6.9 in the MI group com-
pared to 1.4 in the control subjects. The relative risk for MI 
between the highest and lowest quartiles of the apnea index 
was 23.3 (95% CI 3.9–139.9) (Hung et al 1990).
In a cross-sectional substudy of the Sleep Heart Health 
Study, of the association of SDB with cardiovascular disease 
by Shahar et al (2001) it has been demonstrated in 1,023 
participants, using multivariable adjustments, that sleep 
disordered breathing was more strongly associated with 
self-reported heart failure and stroke than coronary artery 
disease. In this study the relative odds (95% CI) of heart 
failure, stroke and coronary artery disease for AHI values that 
were considered normal or only mildly increased, were 2.38 
(1.22–4.62), 1.58 (1.02–2.46) and 1.27 (0.99–1.62) respec-
tively and therefore suggesting only a modest to moderate 
effect on cardiovascular disease.
OSA and cardiac dysfunction
Earlier studies have demonstrated an association with LV 
dysfunction and OSA. These have been explained largely on 
the decreases in intrathoracic pressure during inspiration in 
patients with OSA. It has been demonstrated that large and 
sustained decreases in intrathoracic pressures as a result of 
OSA, may affect LV function not only as a result of changes 
in LV ﬁ  lling but also as a result of changes in afterload. 
Decreases in intrathoracic pressure results in increases in 
left ventricular transmural pressure (LVPtm) during systole, 
which in turn increases afterload (diastolic dysfunction) 
(Buda et al 1979). In addition, increases in negative intra-
thoracic pressure swings increase right-sided ﬁ  lling causing 
right ventricular distention with a leftward shift of the inter-
ventricular septum resulting in decreased left-sided ﬁ  lling. 
These observations have therapeutic implications as positive 
end expiratory pressure and continuous positive airway pres-
sure may be a factor in improving pulmonary compliance 
and LV function in these patients (Suter et al 1979). In two 
outpatient studies of patients with stable and asymptomatic 
congestive heart failure, approximately 40%–50% of the 
patient population had OSA or Cheyne Stokes respiration 
with central sleep apnea Naughton and Bradley (1998). In Therapeutics and Clinical Risk Management 2007:3(6) 1109
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a recent randomized study of 258 patients with congestive 
heart failure and central sleep apnea by Bradley et al (2005) 
(CANPAP Trial) assessing the beneﬁ  ts of longer term CPAP 
on morbidity and mortality, CPAP reduced the frequency 
of apneas and hypopneas, increased the minimal and mean 
nocturnal oxygen saturations, and increased ejection frac-
tions and six-minute walk distance. However, there has 
been no effect on morbidity and mortality as measured by 
the heart transplant-free survival between the CPAP group 
versus the control.
With reference to OSA and the different forms of cardiac 
dysfunction, in a study of 68 patients with polysomnographi-
cally conﬁ  rmed OSA, published by Fung et al it has been 
observed, that an abnormal relaxation period on echo Dop-
pler as evidence for diastolic dysfunction, was present in 
37% of patients. In those with diastolic dysfunction there 
was also an association with increasing age, hypertension 
and a lower minimal oxygen saturation during sleep. How-
ever, using multivariate analysis, is has been observed that 
a lower oxygen saturation during sleep was an independent 
predictor of an abnormal relaxation period irrespective of 
age or hypertension. In addition, diastolic dysfunction was 
more prevalent in those with severe OSA (AHI   40 vs   
40) (Fung et al 2002).
In a prospective study of 169 consecutive OSA patients, 
by Laaban et al (2002) on the association of LV systolic 
dysfunction and OSA, using radionuclide studies, it has been 
observed that only 7.7% (13/169) patients had systolic dys-
function, deﬁ  ned as having an LVEF   50%. In this study, 
patients with known cardiac disease were excluded and there 
was no differences in age, body mass index, AHI, nocturnal 
desaturations or the prevalence of systemic hypertension in 
those with LVEF’s of  50% or  50%. It was also shown 
that in about 50% of patients who had been reassessed after 
treatment of their OSA, their LVEF’s had normalized. The 
authors of this study concluded that systolic dysfunction was 
an uncommon/rare consequence of OSA, and that multiple 
potential mechanisms contributed to this, including LV strain 
related to chronic daytime LV dysfunction, hypoxemia and 
impairment of myocardial contractility and possibly noctur-
nal hypertension and catecholamine surges.
Both OSA and Cheyne-Stokes-Respiration with Central 
Sleep Apnea (CSR-CSA) occur in patients with congestive 
heart failure. Unlike in OSA and patients with CHF, CSR-
CSA tends to be a consequence, rather than a cause of the 
CHF. In patients with an increase in pulmonary venous 
congestion, there is an increase in pulmonary vagal affer-
ents, resulting in hyperventilation. This hyperventilation 
results in a reduction in the arterial PaCO2 below the apnea 
threshold resulting in recurrent central apneas. Although 
the former mechanism is controversial, it is believed that 
an increase in sympathetic nervous system activation may 
stimulate hyperventilation resulting in hypocapnea. The 
apneas are terminated when the PaCO2 rises to the ventila-
tory threshold (Heistad et al 1972; Datta et al 1991; Bradley 
and Phillipson 1992).
CSR-CSA in patients with CHF appears to be a marker of 
increased mortality, and this has been demonstrated in at least 
one study published by Hanley et al who showed in a study 
comparing patients of similar degrees of functional status 
and LV ejection fraction, with and without CSR-CSA, that 
the mortality was 56% in those with CSR-CSA compared to 
11% in those without. The most likely mechanism to explain 
this was an increase in sympathetic nervous system activity 
(Hanly and Zuberi-Khokhar 1996).
In a study of 47 asymptomatic patients with LV dys-
function (LVEF  40%), the prevalence of CSA was much 
higher than OSA (55% vs 11%). In addition, the severity of 
CSA was not associated with the severity of hemodynamic 
impairment (Lanfranchi et al 2003).
OSA and arrhythmias
Both bradyarrhythmias and tachyarrhythmias occur in 
patients with OSA. Bradyarrhythmias are said to be more 
common than tachyarrhythmias, and evidence supports the 
presence of hypoxemia for bradyarrhythmias to occur. Apnea 
without hypoxemia does not result in bradyarrhythmias. 
Hypoxemia causes tachycardia during wakefulness and 
during all stages of sleep. The longer the duration of apnea 
and the more severe the oxygen desaturation, the greater 
the association with bradycardia. Further observations by 
Zwillich et al have demonstrated that breath-holding whilst 
breathing air with low oxygen concentrations than room 
air resulted in bradyarrhythmias (Zwillich et al 1982). The 
effect of hypoxemia and lung inﬂ  ation on heart rate appears 
to be under vagal control, and observations by Zwillich et al 
have conﬁ  rmed that pre-treating subjects with atropine before 
breath holding and breathing lower concentrations of oxygen, 
prevented bradyarrhythmias.
During normal sleep the body is in a state of hemody-
namic and autonomic “quiescence” resulting in a decrease in 
myocardial workload. In patients with OSA, the “arousals” 
punctuate this state of autonomic quiescence resulting in 
increased sympathetic activity and increases in blood pressure 
and heart rate. Most arrhythmias occur in those with AHI   
40/hour (Hoffstein and Mateika 1994).Therapeutics and Clinical Risk Management 2007:3(6) 1110
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In a cohort of patients from the Sleep Heart Health Study, 
individuals with severe sleep-disordered breathing have two- 
to fourfold higher odds of complex arrhythmias than those 
without sleep-disordered breathing even after adjustment for 
potential confounders. This sub-study however, did not ﬁ  nd 
a signiﬁ  cant association between OSA and bradyarrhythmias 
(Mehra et al 2006).
In a study of patients with OSA and atrial ﬁ  brillation, 
those patients cardioverted for AF but untreated for OSA, 
there was a doubling of 1 year recurrence rate of their atrial 
fibrillation compared to those patients receiving CPAP 
therapy (Kanagala et al 2003).
OSA, platelet activation, endothelial 
dysfunction and serum biomarkers
Platelet activation is known to be associated with an increase 
in risk of cardiovascular death (Toﬂ  er et al 1987).
Increased platelet activation and aggregation has been 
shown to occur during sleep in patients with OSA, and 
this effect has been shown to be reduced by nasal CPAP 
(Bokinsky et al 1995). Another study conﬁ  rmed increased 
in-vitro platelet aggregability in patients with OSA which 
was reduced by long term treatment with nasal CPAP. This 
therapy also restored the physiologic diurnal pattern of 
platelet aggregability (Sanner et al 2000).
In a review of the evidence for an increase in cardio-
vascular and cerebrovascular disease, many studies have 
also indicated an increase in hemostatic alterations and 
a pro-coagulant state in patients with OSA. Some of the 
mechanisms include an increase in plasma ﬁ  brinogen, platelet 
activation and reduced thrombolytic activity (Von Kanel and 
Dimsdale 2003).
In the Mayo Clinic Proceedings, OSA, as in athero-
scleorosis, has been shown to be associated with an increase 
in CRP, interleukin 6, ﬁ  brinogen and plasminogen activa-
tor inhibitor and reduced ﬁ  brinolytic activity. In addition, 
there has also been leukocyte adhesion and accumulation 
on the endothelial cells (Parish and Somers 2004). Although 
there are no serum markers for OSA, there is evidence of 
an increase in serum homocysteine and C-Reactive Protein 
(CRP) which may be used as a predictor of long term prog-
nosis for cardiovascular disease and response to treatment 
of OSA (Wright et al 1997).
There is increasing evidence to suggest that repeated 
apnea-related hypoxic events similar to hypoxia and reper-
fusion injury, may lead to oxidative stresses which in turn 
result in free radical production and activation of a number 
of cytokines, adhesion molecules and transcription molecules 
such as endothelin-1, vascular endothelial growth factor 
(VGEF), and NF-kappa-B (Lavie 2003; Cummins et al 2006; 
Zamarron-Sanz et al 2006).
Conclusion
Obstructive sleep apnea is a common condition with major 
public health implications. It is commonly associated with 
recognized cardiovascular risk factors such as obesity, hyper-
tension, diabetes and hyperlipidemia. Some studies have 
suggested that OSA may be an independent cardiovascular 
risk factor. However, many epidemiologic studies have failed 
to demonstrate a causal relationship.
Attention to the treatment of the associated co-morbid 
conditions such as obesity, diabetes, hypothyroidism and 
COPD, as well as treatment with nasal CPAP have been 
associated with a reduction in mortality associated with this 
condition.
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